SLC5A2 and hydrops fetalis: SGLT-2 inhibitors have well-established benefits in individuals with HF, regardless of diabetes status, as demonstrated in several long-term, dedicated HF trials across a wide spectrum of HF patients, including those with reduced and preserved ejection fraction [24].